Feb 14 (Reuters) - Intercept Pharmaceuticals Inc:
* INTERCEPT PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* REGENERATE TRIAL IN NASH FIBROSIS ON TRACK TO REPORT DATA IN 1H19
* PROJECTS NON-GAAP ADJUSTED OPERATING EXPENSES OF $390 MILLION TO $410 MILLION FOR FISCAL YEAR ENDING DEC 31, 2018
* QTRLY NET LOSS PER COMMON AND POTENTIAL COMMON SHARE $4.43
* Q4 EARNINGS PER SHARE VIEW $-3.55, REVENUE VIEW $39.0 MILLION — THOMSON REUTERS I/B/E/S
* Q4 REVENUE $37.7 MILLION Source text for Eikon: Further company coverage: